RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

Core Points - The New York Supreme Court upheld its ruling in favor of RedHill Biopharma, dismissing Kukbo Co. Ltd's defense and confirming Kukbo's breach of agreements [1][2] - RedHill has been awarded approximately $10 million, which includes an original award of $8.25 million and an additional $1.82 million for legal costs and expenses [1][2] - RedHill also secured an attachment grant from Korea's Incheon District Court, allowing for the seizure of Kukbo's assets to prevent disposal before judgment enforcement [2] Company Overview - RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology [3] - The company promotes the FDA-approved drug Talicia for treating H. pylori infections in adults [3] - Key clinical programs include opaganib for various indications, RHB-204 for Crohn's disease, RHB-107 for symptomatic COVID-19, and RHB-102 for chemotherapy-induced nausea [3]